These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4004761)

  • 1. Red cell ghost-entrapped deferoxamine as a model clinical targeted delivery system for iron chelators and other compounds.
    Green R
    Bibl Haematol; 1985; (51):25-35. PubMed ID: 4004761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
    Green R; Miller J; Crosby W
    Blood; 1981 May; 57(5):866-72. PubMed ID: 7214016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of desferrioxamine entrapped in red cell ghosts.
    Green R; Lamon J; Curran D
    Lancet; 1980 Aug; 2(8190):327-30. PubMed ID: 6105474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy.
    Ropars C; Teisseire B; Avenard G; Chassaigne M; Hurel C; Girot R; Nicolau C
    Ann N Y Acad Sci; 1985; 445():304-15. PubMed ID: 3860134
    [No Abstract]   [Full Text] [Related]  

  • 5. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation in red cell ghosts.
    Smith GN
    Lancet; 1981 Jan; 1(8213):222-3. PubMed ID: 6109889
    [No Abstract]   [Full Text] [Related]  

  • 8. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation in red cell ghosts.
    Smith GN
    Lancet; 1980 Dec 20-27; 2(8208-8209):1363. PubMed ID: 6109171
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias.
    Kwiatkowski JL; Cohen AR
    Hematol Oncol Clin North Am; 2004 Dec; 18(6):1355-77, ix. PubMed ID: 15511620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extremely high avidity association of Fe(III) with the sickle red cell membrane.
    Shalev O; Hebbel RP
    Blood; 1996 Jul; 88(1):349-52. PubMed ID: 8704194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
    Tyagi P; Kumar A; Gupta D; Singh H
    AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
    Nelson SC; Hennessy JM; McDonough EA; Guck KL
    J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of iron overload in the pediatric patient.
    Cohen A
    Hematol Oncol Clin North Am; 1987 Sep; 1(3):521-44. PubMed ID: 3329185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
    Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.